AI-powered natural product discovery platform for drug development
Enveda combines wet-lab automation (NMR, LC-MS, HPLC) with ML infrastructure (PyTorch, Databricks, Azure) to mine unexplored molecules from living organisms for drug discovery. The hiring mix—research-heavy with emerging AI and data roles, plus a VP-level AI Innovation Director—reveals a company scaling from molecular characterization toward ML-driven lead optimization. Pain points cluster around workflow automation and data quality (mis-annotations, inventory), not raw compute.
Notable leadership hires: AI Innovation Director, CMC Director
Enveda is a biotech company founded in 2019 that discovers drug candidates by analyzing chemical structures produced by natural organisms, building what it describes as a database of chemical biodiversity. The platform applies AI and computational chemistry to identify promising molecules and advance them toward clinical trials. The company operates across three layers: laboratory automation (NMR and mass spectrometry), computational modeling (machine learning on spectral and structural data), and translational research (lead optimization and preclinical evaluation). Based in Boulder, CO with 201–500 employees, Enveda sells into pharma R&D organizations seeking faster, lower-cost pathways to drug discovery.
Enveda's core stack spans lab automation (LC-MS, HPLC, UPLC-MS, NMR via iConnNMR), data processing (Python, Pandas, NumPy), ML (PyTorch), analytics (Databricks, Azure), and SAP for ERP. Vue handles front-end interfaces.
Active projects focus on NMR automation for natural product structure elucidation, machine learning for mass spectrometry, lead generation and optimization, AI-driven preclinical research strategies, and integrating AI across translational sciences pipelines.
Other companies in the same industry, closest in size